Fig 4.

Model for acquired resistance to platinum chemotherapy by secondary mutations restoring BRCA1/2. Secondary mutation is hypothesized to occur as a result of DNA-damaging chemotherapy, either from primary adjuvant therapy of the ovarian carcinoma or from previous chemotherapy for a separate carcinoma such as breast. This population of cells with restored BRCA1/2 and improved DNA repair is either induced or selected by adjuvant platinum therapy. Adapted with permission from Sakai et al.¹⁸